SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-16-750541
Filing Date
2016-10-28
Accepted
2016-10-28 06:10:08
Documents
13
Effectiveness Date
2016-10-28

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT PERTAINING TO A MERGER d201065ddefm14a.htm DEFM14A 3462536
2 GRAPHIC g201065cn1.jpg GRAPHIC 2020
3 GRAPHIC g201065g02a82.jpg GRAPHIC 45210
4 GRAPHIC g201065g10f31.jpg GRAPHIC 54045
5 GRAPHIC g201065g11f40.jpg GRAPHIC 50369
6 GRAPHIC g201065g23s39.jpg GRAPHIC 39779
7 GRAPHIC g201065g42s45.jpg GRAPHIC 21001
8 GRAPHIC g201065g46f91.jpg GRAPHIC 42485
9 GRAPHIC g201065g50r73.jpg GRAPHIC 34280
10 GRAPHIC g201065g56w12.jpg GRAPHIC 82001
11 GRAPHIC g201065in2.jpg GRAPHIC 5395
12 GRAPHIC g201065ma4.jpg GRAPHIC 6736
13 GRAPHIC g201065te3.jpg GRAPHIC 4846
  Complete submission text file 0001193125-16-750541.txt   3999355
Mailing Address 3181 PORTER DRIVE PALO ALTO CA 94304
Business Address 3181 PORTER DRIVE PALO ALTO CA 94304 650-855-6777
Carbylan Therapeutics, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-36830 | Film No.: 161956866
SIC: 2834 Pharmaceutical Preparations